	Dec 2024	Sep 2024	Dec 2023	Change QoQ%	Change YoY%
Total Revenue Qtr	85.06	90.26	78.71	-5.8%	8.1%
Operating Profit Qtr	17.50	19.66	16.69	-11.0%	4.9%
Net Profit Qtr	8.53	8.47	7.69	0.7%	10.9%
Earning Per Share Adjusted latest Qtr	8.22	8.16	7.41	0.7%	10.9%

* Consolidated data

Detailed Results

Kwality Pharmaceuticals Ltd.

31 Jan 2025

680.25

5.13%

Board Meeting

Kwality Pharmaceuticals Ltd - 539997 - Board Meeting Outcome for SUBMISSION OF UNAUDITED FINANCIAL RESULTS FOR …

BSE India

Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 ('Listing Regulations'), this is to inform your that Board of Directors in its meeting held today i.e., January 31, 2025, have inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024, along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith.

pdf

Kwality Pharmaceuticals Ltd.

21 Jan 2025

680.25

5.13%

Company Update

Kwality Pharmaceuticals Ltd - 539997 - KWALITY PHARMA RECEIVED SFDA APPROVAL FOR ITS GENERAL INJECTABLES AND …

BSE India

KWALITY PHARMA RECEIVED SFDA APPROVAL FOR ITS GENERAL INJECTABLES AND BETA LACTAM (UNIT 1 & 2 IN AMRITSAR).

pdf

Kwality Pharmaceuticals Ltd.

20 Jan 2025

680.25

5.13%

Board Meeting

Kwality Pharmaceuticals Ltd - 539997 - Board Meeting Intimation for Declaring Standalone And Consolidated Unaudited Financial …

BSE India

Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine months ended December 31, 2024 along with Limited Review Report.

pdf